# An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

> **NCT01585987** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 143 (actual)

## Conditions studied

- Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Best Supportive care (BSC)

## Key facts

- **NCT ID:** NCT01585987
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-07
- **Final completion:** 2015-04
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2016-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01585987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01585987, "An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01585987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*